Last edition
News about "Investigational New Drug (IND"
VarmX and CSL Sign Deal Worth up to USD 2.2 Billion
Under the agreement, CSL will fully fund clinical development of VMX-C001 and pay VarmX shareholders USD 117 million upfront for an exclusive option to acquire VarmX, in a transaction worth up to USD 2.2 billion
Investigational New Drug (IND) | 17/09/2025 | By Dineshwori
SK bioscience Files IND for Global Phase 3 Trial of Two-Dose Varicella Vaccine
SK bioscience's Phase 3 clinical trial of SKYVaricella aims to evaluate the immunogenicity and safety of the 2-shot varicella vaccine in roughly 800 children aged 12 months to 12 years, with completion targeted by 2027.
Investigational New Drug (IND | 02/09/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy